In 2022, a research group completed the largest trial in humans so far using exenatide, another GLP-1 agonist drug.

2022年，一个研究小组使用另一种GLP-1促效药艾塞那肽完成了迄今为止最大规模的人体试验。

The researchers found that people with alcohol use disorder who took exenatide had less activity in the brain's reward centers when they were shown pictures of alcohol — which is an indication that they craved it less.

研究人员发现，服用艾塞那肽的酒精使用障碍患者，当他们看到酒精的照片时，大脑奖励中心的活动较少，这表明他们对酒精的渴望较少。

It took more than a decade before exenatide, a synthetic version of the lizard hormone, created by Eli Lilly, an American pharma giant, and Amylin Pharmaceuticals, a biotech firm, was approved to treat diabetes in America.

由美国制药巨头礼来公司和生物科技公司 Amylin Pharmaceuticals 研制的蜥蜴激素合成药物艾塞那肽，花了十多年的时间才在美国获准用于治疗糖尿病。